PLEASE SEE ORIGINAL REDDIT POST FOR IN-DEPTH SUMMARY: https://www.reddit.com/r/pennystocks/comments/1ix9hi0/lxrx_dd_update_070_sp_biopharma_with_8261/

This report is provided by Montgolfier Stocks, a free & professional task-oriented community.

Whilst we are confident, the risks involved may be considered high as the stock's performance relies upon a positive data readout. Do your own due-diligence before making any investment decision.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

$LXRX DD

Primary DD https://docs.google.com/document/d/117ILkfcvuS8bhmYQmRGJbUFCA9vYvQn9vc9hfcJ2UVs/edit?usp=sharing

Update DD https://docs.google.com/document/d/1xn9HyClI2lf0pZMlciJMi3LnkowysUMznOHulZcKD5A/edit?usp=sharing

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

"Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain"

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

Update

Lexicon Pharmaceuticals ($LXRX) announced today that topline results from its Phase 2b study of LX9211 will drop tomorrow, March 3, 2025.

This catalyst, released tomorrow, could redefine the stock’s trajectory, carrying 4x the impact of Phase 1 results according to industry norms.

With a high short interest of 10.21 days to cover (42,000,000 shares on a daily average of 4,000,000), a positive readout could lead to a huge short-squeeze event.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

For new readers

$LXRX is a biotech play centered on LX9211, a novel non-opioid drug for diabetic peripheral neuropathic pain (DPNP). It’s backed by heavy institutional ownership (82.6%, $235.8M), boasts the highest options volatility on NASDAQ (IV30 at 321%), and has significant short interest (23.61% of float, 43M shares).

This mix suggests a low-risk entry with explosive upside potential if tomorrow’s results impress.T

The stakes are high: positive data could spark a short squeeze (given the 10.42 days-to-cover and low retail float (58.7M shares)). With strong market anticipation and institutional confidence, tomorrow’s reveal is a crucial inflection point for $LXRX.

Please read our primary DD, update DD and original post for full information. Aside from this, do your own due-diligence.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━